Nymox Pharmaceutical Corporation is focused on the exploration and advancement of treatments and diagnostics, particularly targeting the unmet requirements of the aging male demographic in developed nations. The company's primary drug candidate for benign prostatic hyperplasia (BPH), Fexapotide Triflutate (FT), has successfully completed Phase 3 development across over 70 clinical centers in the United States, encompassing more than 1700 patients throughout the entire clinical progression. Presently, the company is preparing to seek approval in significant economies worldwide, including the United States and Europe.